Payment overview · 2025
General Payments
$321.23
16 reported records · 11 companies
Healthcare provider profile · identity verified
Timothy S Brooks, DO
Allopathic & Osteopathic Physicians|Family Medicine · CLARION, PA · NPI 1558365189
Verified facts
What the public records show
CMS Open Payments records show Timothy S Brooks, DO received $321.23 in general payments during 2025 across 16 reported records.
Lilly USA, LLC accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $79.95 | 24.9% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $48.47 | 15.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.68 | 10.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.41 | 7.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.59 | 7.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.98 | 6.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.96 | 6.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.71 | 6.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.91 | 5.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.31 | 4.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.26 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $321.23 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $79.95 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $79.95 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $48.47 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.41 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.41 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 125 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 78 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 172 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
172 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
125 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 657 | 153 |
| Omeprazole | Omeprazole | 394 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 360 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 349 | 79 |
| Lisinopril | Lisinopril | 308 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 302 | 56 |
| Gabapentin | Gabapentin | 260 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 259 | 53 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 237 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 228 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 225 | 53 |
| Sertraline Hcl | Sertraline Hcl | 194 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 46 |
| Losartan Potassium | Losartan Potassium | 180 | 46 |
| Simvastatin | Simvastatin | 173 | 44 |
| Ozempic | Semaglutide | 172 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 55 |
| Metformin Hcl Er | Metformin Hcl | 169 | 30 |
| Glipizide Er | Glipizide | 157 | 28 |
| Furosemide | Furosemide | 153 | 33 |
| Meloxicam | Meloxicam | 149 | 32 |
| Metformin Hcl | Metformin Hcl | 139 | 36 |
| Eliquis | Apixaban | 125 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 111 | 21 |
| Tramadol Hcl | Tramadol Hcl | 110 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 15 |
| Carvedilol | Carvedilol | 102 | 25 |
| Xarelto | Rivaroxaban | 102 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 23 |
| Alendronate Sodium | Alendronate Sodium | 91 | 19 |
| Jardiance | Empagliflozin | 89 | 17 |
| Allopurinol | Allopurinol | 85 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 16 |
| Trazodone Hcl | Trazodone Hcl | 85 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 21 |
| Potassium Chloride | Potassium Chloride | 81 | 16 |
| Farxiga | Dapagliflozin Propanediol | 78 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 15 |
| Buspirone Hcl | Buspirone Hcl | 75 | 13 |
| Montelukast Sodium | Montelukast Sodium | 73 | 17 |
| Benazepril Hcl | Benazepril Hcl | 72 | 18 |
| Famotidine | Famotidine | 72 | 20 |
| Naproxen | Naproxen | 71 | 14 |
| Atenolol | Atenolol | 70 | 16 |
| Valsartan | Valsartan | 69 | 14 |
| Amoxicillin | Amoxicillin | 68 | 53 |
| Sucralfate | Sucralfate | 66 | 14 |
| Prednisone | Prednisone | 64 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 16 |
| Bumetanide | Bumetanide | 61 | 15 |
| Synthroid | Levothyroxine Sodium | 61 | 15 |
| Trulicity | Dulaglutide | 61 | suppressed |
| Lorazepam | Lorazepam | 57 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 13 |
| Warfarin Sodium | Warfarin Sodium | 55 | 11 |
| Finasteride | Finasteride | 54 | 12 |
| Clonidine Hcl | Clonidine Hcl | 53 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | suppressed |
| Alprazolam | Alprazolam | 52 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 39 |
| Baclofen | Baclofen | 50 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Rybelsus | Semaglutide | 48 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 47 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 17 |
| Ezetimibe | Ezetimibe | 46 | suppressed |
| Azithromycin | Azithromycin | 45 | 39 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 14 |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 43 | suppressed |
| Nifedipine Er | Nifedipine | 42 | suppressed |
| Premarin | Estrogens, Conjugated | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Ibuprofen | Ibuprofen | 40 | suppressed |
| Celecoxib | Celecoxib | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Methocarbamol | Methocarbamol | 37 | 20 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 26 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Fluconazole | Fluconazole | 27 | 13 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 20 |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 18 |
| Brilinta | Ticagrelor | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 14 |
| Colchicine | Colchicine | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Cefadroxil | Cefadroxil | 17 | 15 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 14 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Olanzapine | Olanzapine | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rytary | Carbidopa/Levodopa | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $321.23 · 16 records | Lilly USA, LLC | CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, PROLIA, Rybelsus, TRELEGY ELLIPTA, XIFAXAN, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error